टीकाकरण संदर्भ

New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines

Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).

Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.

अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:

MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines

द्वारा राचेल मैकगायर

New immunisation reference page: Moderna COVID-19 vaccine

Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.

Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.

अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:

MVEC: Moderna COVID-19 vaccine

द्वारा राचेल मैकगायर

New immunisation reference page: COVID-19 mixed vaccine schedules

With the emergence of variant COVID-19 strains, global vaccine supply issues, and the need to rapidly immunise the population, a number of clinical trials are investigating the option of “mixed schedules”. Mixed schedules have been used previously in other vaccination strategies and involve the administration of different vaccine brands to complete a vaccine course.

Our new reference page explores the clinical trials underway which aim to determine the safety of mixed scheduling, the immunogenicity, as well as the recommendations for intervals between doses.

Due to a lack of available data, mixed vaccine schedules are not currently approved in Australia however are in use in Canada and across Europe.

अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:

MVEC: COVID-19 mixed vaccine schedules

द्वारा राचेल मैकगायर

New immunisation reference page: COVID-19 vaccine delivery: workforce training and application process

द्वारा ऐलिस ब्लैक

New immunisation reference page: COVID-19 vaccination in children

COVID-19 infections have generally produced more severe disease outcomes in adults and the older population, with children generally experiencing milder symptoms. For this reason, initial COVID-19 vaccine clinical trials and vaccine rollouts focused on the adult population.  However, it is recognised that in order to achieve herd immunity within the community, the vaccination of children needs to be considered.

Our new reference page outlines the importance of conducting paediatric focused COVID-19 vaccine clinical trials and summarises the trials that are currently underway.

अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:

MVEC: बच्चों में COVID-19 टीकाकरण

द्वारा राचेल मैकगायर

Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments

Anaphylaxis following immunisation is extremely rare but can be life-threatening if not managed effectively. There are many conditions with similar presentations to anaphylaxis without being true anaphylaxis (eg. vasovagal, anxiety, vocal cord dysfunction) which can make the diagnosis difficult.

The Department of Health and the VicSIS network have put together Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments. This helpful resource provides a comparison of signs and symproms, as well as highlights the importance of measuring tryptase levels in patients with suspected anaphylaxis.

This guidance can be found in the resources section of the below reference page:

एमवीईसी: कोविड-19 टीके और एलर्जी

द्वारा राचेल मैकगायर

New immunisation reference page: COVID-19 vaccines in people with immunocompromise

Despite vaccination being recommended, there is currently minimal data on the safety and efficacy of COVID-19 vaccines in the immunocompromised population. In principle, there are no theoretical safety risks and no vaccine safety signals have been identified for vaccinated people with immunocompromise को date.  Similar to responses following the administration of other inactivated vaccines in immunocompromised people, a reduced efficacy may occur following vaccination against COVID-19. 

Our new reference page collates the various recommendations and guidance available for a broad group of immunocompromising conditions and therapies, as well as providing specific recommendations and/or links where available. 

अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:

एमवीईसी: प्रतिरक्षाविहीनता वाले लोगों में कोविड-19 टीके

द्वारा राचेल मैकगायर

New immunisation reference page: Adverse events following COVID-19 immunisation

All immunisations are medications and all medications do have side effects. For each vaccine there is a known list of common or expected adverse events following immunisation (AEFI) and then a smaller list of serious side effects. Reporting significant adverse events is important to allow for signal detection and investigation as part of post-licensure vaccine safety monitoring.

Our new reference page explores what sort of reactions are common and expected following COVID-19 immunisation, and what sort of reactions warrant reporting.

For more information please refer to the following:

एमवीईसी: सीओवीआईडी-19 वैक्सीन प्रतिकूल घटनाएं

द्वारा राचेल मैकगायर